Canine Atopic Dermatitis Market by Product and Geography - Forecast and Analysis 2022-2026

The canine atopic dermatitis market share is expected to increase by USD 319.37 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.75%.

This canine atopic dermatitis market research report extensively covers market segmentation by product (antihistamines, glucocorticoids, progestational compounds, and others) and geography (North America, Europe, Asia, and ROW).

The canine atopic dermatitis market report also offers information on several market vendors, including Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc. among others. Furthermore, this report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.

What will the Canine Atopic Dermatitis Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Canine Atopic Dermatitis Market Size for the Forecast Period and Other Important Statistics

 

Canine Atopic Dermatitis Market: Key Drivers, Trends, and Challenges

The increase in pet humanization is notably driving the canine atopic dermatitis market growth, although factors such as stringent global regulatory requirements may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the canine atopic dermatitis industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Canine Atopic Dermatitis Market Driver

• The increase in pet humanization is one of the factors supporting the canine atopic dermatitis market growth. 
• The owners of pets look for good healthcare products and veterinary services to improve the health and lifespan of their pets. This is evident in both emerging as well as developed markets.
• Globally, pet owners are ensuring that the quality of ingredients and manufacturing standards of all pet care products are as good as those intended for and used by people.
• Pet owners belonging to the younger generation are making efforts to pamper their pets.
• The expectations and demands for pet wellness products are constantly increasing, which is driving the demand for drugs for the treatment of canine atopic dermatitis during the forecast period.

Key Canine Atopic Dermatitis Market Trend

• The increase in M&A is another factor supporting the canine atopic dermatitis market growth. 
• In March 2019, Elanco Animal Health Inc. completed its separation from Eli Lilly and Co.
• In March 2021, Virbac acquired certain projects related to the development of innovative parasiticide products from Elanco. In addition, Virbac obtained global rights to two companion animal products, namely Itrafungol and Clomicalm.
• In 2020, The European Commission approved Elanco Animal Health Inc.'s proposed acquisition of Bayer AG's Animal Health Division. This acquisition led to the creation of the second-largest animal health company globally.
• The increase in M&A will fuel the growth of the drugs for the treatment of the canine atopic dermatitis market during the forecast period.

Key Canine Atopic Dermatitis Market Challenge

• The stringent global regulatory requirements is hindering the canine atopic dermatitis market growth. 
• Manufacturers are required to follow the implemented stringent regulatory requirement to avoid consequences. 
• The new animal drugs include an approved application before being imported from one country to another.
• The drug applications include approved new animal drug application (NADA), abbreviated NADA (ANADA), investigational new animal drug application (INAD), generic investigational new animal drug application (JINDA), conditional approval (CNADA), or index listing.
• The presence of such stringent regulations can hamper the demand for medications to treat canine atopic dermatitis during the forecast period.

This canine atopic dermatitis market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the canine atopic dermatitis market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the canine atopic dermatitis market during the forecast period.

Who are the Major Canine Atopic Dermatitis Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Bioceltix Spolka Akcyjna
• Ceva Sante Animale
• Dechra Pharmaceuticals Plc
• Elanco Animal Health Inc.
• Novartis AG
• Toray Industries Inc.
• Vetoquinol UK Ltd.
• Vimian Group AB
• Virbac
• Zoetis Inc.

 

This statistical study of the canine atopic dermatitis market encompasses successful business strategies deployed by the key vendors. The canine atopic dermatitis market is fragmented and the vendors are deploying growth strategies such as low pricing strategies and strengthening their customer base in local or regional markets to compete in the market.

Product Insights and News

• Toray Industries Inc. - The company offers solutions for canine atopic dermatitis which have active ingredients such as canine interferon-y that are genetically modified and used under the prescription and guidance of a veterinarian, under the brand name of Interdog.
• Vetoquinol UK Ltd. - The company offers solutions for canine atopic dermatitis that help with skin infections of Staphylococcus intermedius, Malassezia pachydermatis, Microsporum canis, Microsporum gypseum, and Trichophyton mentagrophytes in dogs and cats, under the brand name of Dermichilor.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The canine atopic dermatitis market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Canine Atopic Dermatitis Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the canine atopic dermatitis market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

• Research and development (R&D) and drug discovery
• Integration and product development
• Manufacturing
• Outbound logistics
• Marketing and sales
• Support services
• Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

 

Which are the Key Regions for Canine Atopic Dermatitis Market?

For more insights on the market share of various regions Request for a FREE sample now!

37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the canine atopic dermatitis market in North America. Market growth in this region will be slower than the growth of the market in Europe.

The large interest in pet ownership will facilitate the canine atopic dermatitis market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

Studies have found that SAR-CoV-2, the virus responsible for COVID-19, can be spread from humans to pets in some situations. Hence, a few veterinary diagnostic laboratories have developed COVID-19 diagnostics tests for dogs and cats, but these are not available as routine tests as yet. Moreover, the adoption of pets in the region has increased during the COVID-19 pandemic. Thus, the increasing demand for pets will drive market growth during the forecast period.

What are the Revenue-generating Product Segments in the Canine Atopic Dermatitis Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The canine atopic dermatitis market share growth by the antihistamines segment will be significant during the forecast period. Antihistamines are defined as drugs that are commonly used to treat allergies. They are also beneficial for controlling skin allergies in dogs. Hence, antihistamine drugs are highly cost-effective, easily available, and are the most commonly prescribed type of medication for the treatment of allergies, which will fuel the growth of this segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the canine atopic dermatitis market size and actionable market insights on post COVID-19 impact on each segment.

 

Canine Atopic Dermatitis Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 7.75%
Market growth 2022-2026	$ 319.37 million
Market structure	Fragmented
YoY growth (%)	4.03
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 37%
Key consumer countries	US, Canada, UK, Brazil, Germany, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Bioceltix Spolka Akcyjna, Ceva Sante Animale, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Novartis AG, Toray Industries Inc., Vetoquinol UK Ltd., Vimian Group AB, Virbac, and Zoetis Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Canine Atopic Dermatitis Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive canine atopic dermatitis market growth during the next five years
• Precise estimation of the canine atopic dermatitis market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the canine atopic dermatitis industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of canine atopic dermatitis market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch